Moreover, not only the suppression of FASN inhibits ALL cells growth but also produces a remarkable impairment of PD-L1 expression, indicating the potential role of FASN inhibitors in antileukemia immunotherapy (140). Here, FASN is linked to acute lymphoblastic leukemia.